Tocqueville Asset Management L.P. Makes New Investment in RxSight, Inc. $RXST
Tocqueville Asset Management L.P. has made a new investment in RxSight, Inc. (NASDAQ:RXST), acquiring 265,000 shares valued at approximately $1.28 million, representing 0.64% of the company. Despite beating Q2 earnings estimates, RxSight remains unprofitable with a negative net margin. Institutional investors collectively own 78.78% of the company, and analysts have a consensus "Reduce" rating with an average price target of $8.37.
Steven Cohen’s Point72 discloses RxSight (RXST) stake
Steven Cohen's Point72 Asset Management, along with Point72 Capital Advisors, Inc., has disclosed a beneficial ownership of 2,487,468 shares of RxSight, Inc. (RXST) common stock, representing 6.0% of the class. This stake was reported as of August 18, 2026, through a Schedule 13G filing, indicating shared voting and dispositive power. The shares are managed by Point72 Asset Management via Point72 Associates, LLC, an investment fund.
Vitruvian Partners LLP Purchases New Holdings in RxSight, Inc. $RXST
Vitruvian Partners LLP has acquired a new stake of 278,865 shares in RxSight, Inc. (NASDAQ:RXST) during the second quarter, making it their 8th largest holding and representing approximately 0.7% of their investment portfolio. Despite this new investment and RxSight beating quarterly earnings expectations, the company currently holds an average analyst rating of "Reduce" with a target price of $8.37. Other institutional investors have also adjusted their positions in RxSight, with institutional ownership reaching 78.78%.
RxSight (NASDAQ: RXST) ex-director to sell 11,890 shares
RxSight, Inc. (NASDAQ: RXST) has reported through a Form 144 SEC filing that former director Raymond W. Cohen intends to sell 11,890 shares of common stock. The proposed sale, valued at $75,748.81, will be executed via Morgan Stanley Smith Barney LLC on NASDAQ. This disclosure signals a potential insider sale under Rule 144, rather than a company-initiated transaction.
Walleye Capital LLC Takes Position in RxSight, Inc. $RXST
Walleye Capital LLC has acquired a new stake of 358,036 shares in RxSight, Inc. (NASDAQ:RXST) during the second quarter, valued at approximately $1.73 million. Despite institutional ownership of 78.78%, RxSight carries a consensus "Reduce" rating from analysts with an average price target of $8.37. The company recently reported better-than-expected quarterly revenue and a narrower loss per share, though it continues to operate with negative margins and is projected to lose $1.31 per share for the current year.
RxSight, Inc. (NASDAQ:RXST) Receives Average Recommendation of "Reduce" from Brokerages
RxSight, Inc. (NASDAQ:RXST) has received a consensus "Reduce" rating from twelve analysts, with an average 12-month price target of $8.37. Despite several firms lowering their price targets, the company's latest quarterly results surpassed expectations. Institutional investors hold a significant 78.78% stake in RxSight.
Stifel cuts RxSight stock price target on competitive headwinds
Stifel has lowered its price target for RxSight Inc. (NASDAQ:RXST) from $8.00 to $7.00, while maintaining a Hold rating due to anticipated competitive headwinds over the next 12-18 months. Despite the company surpassing second-quarter 2026 earnings and revenue expectations, and the new CEO Aziz Mottiwala bringing relevant experience, RxSight withdrew its full-year guidance, which led to a stock decline. The firm anticipates a challenging environment for RxSight to expand beyond its niche given the evolving multifocal IOL market.
Stifel Nicolaus Lowers RxSight (NASDAQ:RXST) Price Target to $7.00
Stifel Nicolaus has reduced its price target for RxSight (NASDAQ:RXST) from $8.00 to $7.00, while maintaining a "hold" rating, suggesting an 11.82% potential upside. Despite the lowered target, RxSight recently reported better-than-expected quarterly results, surpassing analyst estimates for both earnings per share and revenue. The company currently holds a "Reduce" consensus rating from analysts, with an average price target of $8.37.
Stifel cuts RxSight stock price target on competitive headwinds
Stifel lowered its price target for RxSight Inc. (NASDAQ:RXST) to $7.00 from $8.00 due to competitive headwinds, while maintaining a Hold rating. Despite the stock appearing undervalued and recent Q2 2026 earnings beating expectations, the company withdrew its full-year guidance. Stifel anticipates a turnaround will take time, given the evolving multifocal IOL landscape.
RxSight (RXST) offers to swap 4.08M underwater options for new awards
RxSight, Inc. has initiated an employee stock option exchange offer for up to 4,083,693 underwater options issued under its 2021 Equity Incentive Plan. Eligible U.S.-based employees can exchange options with exercise prices at or above $6.00 (or $10.00 for named executive officers) for new awards, which will be restricted stock units for non-executive employees and new stock options for named executive officers. The offer aims to replace outstanding, unexercised options with new awards, conditional on employee participation and company acceptance.
RxSight Reports Q2 Financial Results, Provides Update on 2026 Outlook
RxSight, Inc. announced its financial results for Q2 2026, reporting $33.7 million in total revenue, including $6.5 million from a collaboration with Alcon. Product sales decreased by 19 percent due to competitive pressures. The company also announced a leadership transition and withdrew its 2026 guidance, expecting to resume formal guidance in early 2027.
Wall Street Zen Upgrades RxSight (NASDAQ:RXST) to Hold
Wall Street Zen has upgraded RxSight (NASDAQ:RXST) from a "sell" to a "hold" rating, while the broader analyst consensus remains "Reduce" with an $8.59 average price target. This upgrade follows RxSight reporting better-than-expected quarterly results, with a loss of $0.29 per share against an estimated $0.33 loss and revenues of $33.74 million surpassing the $32.55 million estimate. Institutional investors currently hold 78.78% of the company's shares.
Levi & Korsinsky Notifies RxSight, Inc. (RXST) Investors - Lead Plaintiff Deadline on September 22, 2025
Levi & Korsinsky LLP has announced a lead plaintiff deadline of September 22, 2025, for investors of RxSight, Inc. (RXST) who suffered losses. The class action securities lawsuit alleges that RxSight made false statements regarding "adoption challenges," overstated product demand, and was unlikely to meet its financial guidance for fiscal year 2025. Investors are encouraged to seek recovery under federal securities laws.
RxSight, Inc. Stock 12‑Month Price Target Cut to $7.91, Implies 26% Upside
RxSight, Inc.'s average stock price target has been reduced from $8.06 to $7.91 by 8 analysts, with individual forecasts ranging from $6 to $11 per share. This new target suggests a potential upside of approximately 26% based on the recent closing price. The consensus rating for RxSight, Inc. remains "Hold" among 10 analysts.
Earnings To Watch: RxSight Inc (RXST) Q2 2026 -- GF Value Sees 519% Upside
RxSight Inc (NASDAQ:RXST) is scheduled to release its Q2 2026 earnings on August 7, 2026, with revenue expected at $32.55 million and earnings at $-0.32 per share. GuruFocus estimates a significant upside of 518.60% for RXST based on its GF Value of $38.91, despite a current "Hold" recommendation from brokerage firms. The company's revenue and earnings estimates for both 2026 and 2027 have seen upward revisions in the last 90 days.
Rxsight, Inc. Reports Second Quarter 2026 Res
This article is a placeholder indicating that Rxsight, Inc. reported its second quarter 2026 results. The full content of the report is not provided.
Press Release: RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
RxSight, Inc. announced its financial results for the second quarter of 2026. The company also provided an update on its financial outlook for the full year 2026. This press release details their performance and future expectations.
RxSight Q2 Earnings Call Highlights
RxSight reported Q2 revenue of $33.7 million, with product sales down 19% year-over-year excluding collaboration revenue, due to competitive trialing and market headwinds. The new CEO, Aziz Mottiwala, has withdrawn full-year financial guidance to conduct a comprehensive assessment of the business and commercial strategy, with a focus on improving LAL platform adoption and utilization. The company expects to resume formal guidance in early 2027 after reporting Q4 2026 results.
New RxSight lenses are intended to reduce post-surgery office visits
RxSight, Inc. (NASDAQ: RXST) reported Q2 2026 revenue of $33.7 million, flat year-over-year, and a net loss of $12.1 million. The company announced a strategic collaboration with Alcon, appointed a new CEO, and introduced a next-generation Light Adjustable Technology platform with new lenses designed to improve workflow and reduce postoperative office visits. Due to a leadership transition, RxSight withdrew its 2026 guidance, with plans to resume formal guidance in early 2027.
RxSight Q2 FY26 net loss widens 2.6% to $12.1 million; revenue rises 0.3% to $33.7 million
RxSight reported a Q2 FY26 net loss of $12.1 million, a 2.6% increase, despite a 0.3% rise in revenue to $33.7 million. The revenue increase was primarily driven by a $6.5 million license fee, which offset a 19% decline in product sales. The company's product gross margin also fell, and Aziz Mottiwala was named CEO, effective July 20.
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
RxSight, Inc. (RXST) reported a narrower-than-expected Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.21 loss, and surpassed revenue estimates with $33.74 million. Despite beating estimates, the company's shares have fallen 40% year-to-date, while the broader S&P 500 gained 13%. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
Earnings call transcript: RxSight beats Q2 2026 estimates but withdraws guidance
RxSight reported better-than-expected Q2 2026 earnings and revenue, but its stock fell after the company withdrew its full-year guidance due to ongoing pressure in its core business. The ophthalmology company's adjusted EPS beat estimates by $0.25, and revenue topped forecasts, partly aided by a collaboration with Alcon. However, core product revenue declined 19% year-over-year, leading the company to re-evaluate its commercial model.
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
RxSight, Inc. announced its financial results for the second quarter of 2026, reporting total revenue of $33.7 million, which included $6.5 million from its collaboration with Alcon. The company also announced the appointment of Aziz Mottiwala as President and CEO, and revealed plans to develop a next-generation RxSight Light Adjustable Technology platform. Due to the leadership transition and a comprehensive business review, RxSight withdrew its 2026 financial guidance, with plans to resume formal guidance in early 2027.
RxSight, Inc. (RXST) Tops Q2 EPS by 25c
RxSight, Inc. (NASDAQ: RXST) reported strong financial results for Q2, with earnings per share of ($0.11), significantly surpassing analyst estimates of ($0.36) by $0.25. The company's revenue also exceeded expectations, coming in at $33.74 million against a consensus estimate of $32.21 million.
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
RxSight, Inc. reported its financial results for the second quarter of 2026, with total revenue reaching $33.7 million, including $6.5 million from its collaboration with Alcon. The company also announced key strategic developments, such as the appointment of Aziz Mottiwala as CEO and a strategic collaboration with Alcon, while withdrawing its 2026 financial guidance to focus on strengthening commercial execution and business review. Despite a net loss of $(12.1) million, RxSight aims to translate the value of its adjustable lens technology into durable growth, backed by approximately $209 million in cash and short-term investments.
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
RxSight, Inc. (RXST) reported a smaller-than-expected Q2 loss of $0.11 per share, beating the Zacks Consensus Estimate of a $0.21 loss, though it was still a wider loss compared to the previous year. The company also surpassed revenue estimates, posting $33.74 million against an expectation of $32.90 million. Despite these Q2 beats, RxSight shares have fallen significantly this year, and the stock currently holds a Zacks Rank #3 (Hold).
RxSight (RXST): Millennium entities, Israel Englander report 7.3% ownership stake
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a 7.3% ownership stake in RxSight, Inc. (RXST), totaling 3,030,287 shares as of June 30, 2026. The filing indicates that all beneficially owned shares have shared voting and dispositive power, with no sole voting or dispositive power reported by the individual entities. A Joint Filing Agreement among the reporting persons was executed on August 3, 2026.
Bronstein, Gewirtz & Grossman, LLC Is Investigating RxSight, Inc. (RXST) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of RxSight, Inc. (NASDAQ:RXST) securities. The investigation focuses on whether RxSight and its officers engaged in corporate wrongdoing. Investors who purchased RxSight securities before November 7, 2024, and continue to hold them, are encouraged to contact the firm to assist in the investigation.
RxSight, Inc. expected to post a loss of 33 cents a share - Earnings Preview
RxSight, Inc. is projected to report an earnings loss of 33 cents per share. This information comes from a Refinitiv earnings preview. The full article is available on TradingView, which aggregates news from various sources including Reuters.
(RXST) Risk Channels and Responsive Allocation
This article from Stock Traders Daily analyzes Rxsight Inc. (NASDAQ: RXST), highlighting strong near- and mid-term sentiment but a weak long-term outlook. It identifies a mid-channel oscillation pattern and an exceptional 98.0:1 risk-reward setup, targeting a 34.3% gain against 0.4% risk. The report provides AI-generated institutional trading strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Rxsight Inc (RXST) Financial Health: Profitability & Balance Sheet Analysis
Rxsight Inc (RXST) has a current financial score of 6.86, placing it 125 out of 199 in the Healthcare Equipment & Supplies industry. The company's financial status is stable with average operating efficiency, though its latest quarterly revenue decreased by 18.48% year-over-year and net profit saw a 93.94% year-over-year decrease. Key financial metrics like cash and cash equivalents, total assets, and cash flow from operating activities were not fully disclosed.
RXST|Rxsight Inc|Price:5.865|Chg%:-0.185
RxSight, Inc. is a commercial-stage medical technology company that provides customized vision to cataract surgery patients through its proprietary RxSight Light Adjustable Lens system. The article details the company's profile, including its IPO date, CEO, number of employees, address, and key executives with their shareholdings. It also provides information on institutional shareholding, noting that 467 institutions hold approximately 93.24% of the total shares as of Q1 2026.
RxSight Number of Employees 2026 | Employee Count & Headcount Data
RxSight, Inc. (RXST) had approximately 469 employees worldwide as of March 2026, marking a 26.5% growth since 2023 but a 7.3% decline year-over-year in 2026. The company, headquartered in Aliso Viejo, California, is actively hiring with 18 job postings and its workforce is predominantly in the United States. Employee sentiment is negative and declining, and the average salary is $125,376.
Rxsight Inc (RXST) Institutional Confidence
Rxsight Inc (RXST) has an institutional shareholding score of 10.00, placing it first in its industry. Institutional ownership stands at 93.24%, an 11.69% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 1.77% of outstanding shares.
UBS Adjusts Price Target on RxSight to $5.50 From $9, Maintains Neutral Rating
UBS has revised its price target for RxSight (NASDAQ: RXST) to $5.50, down from the previous $9, while maintaining a Neutral rating on the stock. This adjustment reflects a change in the firm's outlook on the company's valuation.
RXST Lowered by UBS - Price Target Reduced to $5.50
UBS has lowered its price target for RxSight Inc (RXST) from $9.00 to $5.50, maintaining a 'Neutral' rating, reflecting a cautious outlook despite the company being deemed 83.4% undervalued by GuruFocus's GF Value. RxSight, which focuses on innovative intraocular lens technology, faces mixed analyst opinions and current unprofitability, although 5 gurus hold positions in the stock with some adding recently. Investors are advised to perform thorough due diligence due to the company's unprofitability and potential value trap.
UBS Adjusts Price Target on RxSight to $5.50 From $9, Maintains Neutral Rating
UBS has revised its price target for RxSight (RXST) shares downwards to $5.50 from the previous $9, while maintaining a Neutral rating on the stock. The adjustment reflects an updated outlook from the analyst firm. This news follows several recent announcements from RxSight, including CEO and management changes, preliminary revenue guidance, and a new collaboration with Alcon for adjustable lenses.
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
RxSight, Inc. (NASDAQ: RXST) has announced a leadership transition effective July 20, 2026, with Aziz Mottiwala taking over as President and Chief Executive Officer. He succeeds Ron Kurtz, M.D., who will continue as Chief Medical Officer. The company believes Mottiwala's extensive commercial leadership experience in eye care will guide RxSight into its next phase of growth, while Dr. Kurtz will focus on advancing technology and clinical value in his new role.
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight, Inc. announced incentive grants to its new President and Chief Executive Officer, Aziz Mottiwala. These grants include stock options for 571,286 shares and restricted stock units (RSUs) for 2,312,138 shares, issued on July 24, 2026, and vest over one to three years. The grants comply with Nasdaq Listing Rule 5635(c)(4) as material inducements for his employment.
Leadership watch: RxSight, Exonate tap new CEOs; CooperVision, Lumenis, and OSU fill top roles
This article details significant leadership changes across several companies and institutions in the eyecare sector. RxSight and Exonate have appointed new CEOs, while CooperVision and Lumenis have filled key executive roles. Additionally, The Ohio State University's College of Optometry announced a new dean, highlighting a range of executive movements in the industry.
Rxsight Inc (RXST) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the major shareholders and institutional holdings of Rxsight Inc (RXST), providing a breakdown of shareholder types, top shareholders, and institutional shareholding trends over time. Key data points include percentages held by investment advisors, hedge funds, and individual investors, along with quarterly changes in institutional ownership and holdings by specific firms like BlackRock and Millennium Management.
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight, Inc. announced inducement stock options and restricted stock units (RSUs) granted to its new President and CEO, Aziz Mottiwala, in connection with his employment. These grants, totaling 571,286 shares for stock options and 2,312,138 shares for RSUs, were made in accordance with Nasdaq Listing Rule 5635(c)(4). The awards have specific vesting schedules over one to three years.
RxSight grants inducement stock options and RSU...
RxSight, Inc. granted new President and CEO Aziz Mottiwala inducement stock options for 571,286 shares and restricted stock units (RSUs) for 2,312,138 shares. These grants, effective July 24, 2026, are part of the company's 2026 Inducement Equity Incentive Plan and are designed to incentivize Mottiwala's leadership in advancing RxSight's adjustable intraocular lens technology. The stock options vest over four years, and the RSUs vest over three years, both tied to specific milestones.
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
RxSight, Inc. (NASDAQ: RXST) announced inducement stock options and restricted stock units (RSUs) granted to its new President and CEO, Aziz Mottiwala, in connection with his employment. These grants, comprising 571,286 shares for stock options and 2,312,138 shares for RSUs, were made on July 24, 2026, and vest over several years as an inducement to his employment, adhering to Nasdaq Listing Rule 5635(c)(4). RxSight is an ophthalmic medical device company known for its Light Adjustable Lens system, which allows post-cataract surgery vision customization.
Levi & Korsinsky Notifies RxSight, Inc. (RXST) Shareholders of Class Action Lawsuit and September 22, 2025 Deadline
Levi & Korsinsky has announced a class action lawsuit against RxSight, Inc. (NASDAQ:RXST) on behalf of shareholders who suffered losses due to alleged securities fraud between May 7, 2024, and July 8, 2025. The lawsuit claims RxSight made false statements and concealed "adoption challenges" and overstated product demand, leading to an unlikely achievement of its 2025 financial guidance. Shareholders have until September 22, 2025, to learn about their rights to potentially recover losses.
RXST|Rxsight Inc|Price:5.205|Chg%:-0.165
This article provides a detailed financial overview of Rxsight Inc. (RXST), including its recent stock performance, financial statements, and key indicators. It highlights the company's Q1 FY2026 earnings forecast with an EPS of -0.35 and revenue of 32.47M, and a current analyst rating of "HOLD." The comprehensive data dashboard allows investors to analyze income statements, balance sheets, and cash flow statements quarter-by-quarter.
Rxsight Inc (RXST) Earnings Forecast: Future EPS & Revenue Growth Estimates
Rxsight Inc (RXST) has an earnings forecast score of 5.80, placing it 185th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $10.00 for RXST, with individual forecasts ranging from $8.00 to $14.00, representing a potential upside of 63.27%. Based on ratings from 10 analysts, the stock currently holds a "Hold" trend.
Form 4 Rxsight Inc For: 24 July By Investing.com
This article from Investing.com is a regulatory filing notification, specifically a Form 4 for Rxsight Inc. dated July 24. It indicates insider transaction activity for the company, though the details of the transactions are not provided within the snippet. The article also includes market data for various indices, commodities, bonds, and shares as of July 25, 2026.
RxSight, Inc. (RXST) awards CEO 2,312,138 RSUs and 571,286 options
RxSight, Inc. (RXST) has granted its President and CEO, Aziz Mottiwala, 2,312,138 restricted stock units (RSUs) and options for 571,286 shares with an exercise price of $5.19 per share. These equity awards, reported in a Form 4 SEC filing, are designed to vest over multi-year schedules contingent on Mottiwala's continued service, aligning his interests with the company's long-term success. The RSUs vest over three years (20%/20%/60%) and the options vest (25% after one year, then monthly) starting July 24, 2026, under the company's 2026 Inducement Equity Incentive Plan.
RxSight Appoints Aziz Mottiwala as President and CEO
RxSight has announced the appointment of Aziz Mottiwala as its new President and CEO, effective July 20, 2026. Mottiwala, with over a decade of experience in ophthalmology and biopharmaceutical commercialization, succeeds Ron Kurtz, MD, who will transition to Chief Medical Officer. This leadership change follows RxSight's recent collaboration with Alcon to develop adjustable presbyopia-correcting IOLs.
